A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
NCT ID: NCT01998893
Last Updated: 2014-12-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
38 participants
INTERVENTIONAL
1997-01-31
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MabThera/Rituxan
rituximab [MabThera/Rituxan]
375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rituximab [MabThera/Rituxan]
375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* centrocytic centroblastic non-Hodgkin's lymphoma stage III-IV;
* relapse after chemotherapy (with or without interferon maintenance therapy).
Exclusion Criteria
* more than 3 relapses of centroblastic centrocytic non-Hodgkin's lymphoma;
* clinically significant cardiac disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cologne, , Germany
Erlangen, , Germany
Göttingen, , Germany
Grenzach-Wyhlen, , Germany
Hanover, , Germany
Homburg/saar, , Germany
München, , Germany
München, , Germany
Münster, , Germany
Stuttgart, , Germany
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M39004
Identifier Type: -
Identifier Source: org_study_id